NCT03725072View on ClinicalTrials.gov

Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

December 5, 2018

Study Completion Date

December 5, 2018

Conditions
Healthy
Interventions
DRUG

Evobrutinib

Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.

Trial Locations (1)

9728 NZ

PRA Health Sciences, Groningen

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03725072 - Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib | Biotech Hunter | Biotech Hunter